A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS). Infants with RDS were randomized to receive beractant or poractant. The primary outcome measure was fraction of inspired oxygen (FiO2) requirement in the first 48 h after surfactant therapy. 58 infants completed the study. The mean gestational ages for the poractant and beractant groups were 29.6+/-3.6 and 29.3+/-2.9 wk, with average birthweights of 1394+/-699 and 1408+/-534 g, respectively. In the first 48 h, infants who received poractant had a lower FiO2 requirement compared to those who received beractant (p=0.018). The prevalence of patent ductus arteriosus (PDA) was lower in the group of infants that received poractant (17%) compared to the group that received beractant (45%) (p=0.02). Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.